STOCK TITAN

Enovis Corp SEC Filings

ENOV NYSE

Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Enovis Corp's SEC filings reveal the financial mechanics behind its orthopedic device business, from surgical implant revenue to rehabilitation equipment margins. Understanding how a medical technology company performs across its business segments requires navigating through specific disclosure patterns unique to the healthcare industry.

The company's 10-K annual reports break down performance between the Prevention & Recovery and Reconstructive segments, showing which product lines drive growth. These filings detail revenue recognition for medical device sales, including timing of surgical implant deliveries and recurring rehabilitation equipment orders. For investors analyzing Enovis's transition from diversified industrial operations to pure-play medical technology, the 10-K provides historical context on this corporate transformation.

Quarterly 10-Q filings track segment performance throughout the year, revealing seasonal patterns in orthopedic procedures that affect implant demand. Medical device companies often see surgical volume fluctuations that impact quarterly results, making these interim reports essential for understanding revenue trends.

8-K filings capture material events including business acquisitions, divestitures, and leadership changes. Enovis's strategic focus on building its orthopedic portfolio means 8-K disclosures often address M&A activity and portfolio adjustments. Executive compensation and governance details appear in proxy statements, documenting how management incentives align with company performance.

Form 4 insider transactions show when executives and directors buy or sell ENOV shares. Tracking these trades provides perspective on insider sentiment regarding the company's medical device strategy and growth prospects.

Our AI-powered summaries translate dense medical device industry disclosures into clear explanations, helping you understand Enovis's orthopedic business without reading through technical accounting treatments.

Rhea-AI Summary

Insider purchase by Enovis executive: Tandy Bradley J, SVP and Chief Legal Officer of Enovis Corporation (ENOV), reported purchasing 3,200 shares of Enovis common stock on 08/22/2025 at a price of $31.41 per share. After the transaction, Mr. Bradley beneficially owned 43,515 shares. The Form 4 was signed via attorney-in-fact on 08/25/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enovis insider purchase disclosed on Form 4. Philip Benjamin Berry, SVP and Chief Financial Officer, purchased 2,500 shares of Enovis Corporation (ticker ENOV) on 08/20/2025 at a price of $29.71 per share. After the transaction, Mr. Berry beneficially owned 116,729 shares. The Form 4 was filed as a single reporting person filing and was signed by attorney-in-fact Brian P. Hanigan on 08/20/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

The filing discloses that multiple American Century entities and the Stowers Institute report material beneficial ownership in Enovis Corporation common stock. American Century Investment Management, Inc., American Century Companies, Inc. and Stowers Institute each report beneficial ownership of 4,737,327 shares, representing 8.3% of the class, with sole voting power of 4,580,116 shares and sole dispositive power of 4,737,327 shares as shown on their cover pages. American Century Capital Portfolios, Inc. reports ownership of 3,060,000 shares, representing 5.4% of the class, with sole voting and dispositive power.

The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. An exhibit shows that the reporting persons consented to a joint filing, and signatures certify the accuracy of the statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Davenport & Co LLC reported beneficial ownership of 2,756,270 shares of Enovis common stock, representing 4.83% of the class. The filer discloses sole voting power over 2,730,225 shares and sole dispositive power over 2,756,145 shares. The statement is filed on Schedule 13G as an investment adviser and indicates the holding is 5% or less of the class.

This filing also contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Enovis Corp. (ENOV) – Form 4 filing dated 08/07/2025

Group President, Recon, Louis Vogt reported one transaction on 08/05/2025. The Form 4 shows an F-code entry—shares withheld by the company to cover tax obligations arising from the net settlement of previously granted restricted stock units.

  • Securities withheld: 460 common shares
  • Price applied for withholding: $26.46 per share
  • Post-transaction direct holdings: 36,385 common shares
The transaction does not represent an open-market sale and therefore has minimal impact on float or insider sentiment. No derivative security activity was reported. Vogt continues to file individually and remains an officer of the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
insider
-
Rhea-AI Summary

Enovis Corporation (ENOV) filed a Form 4 disclosing an insider withholding transaction by reporting person John Kleckner, identified as the company's Principal Accounting Officer. On 08/05/2025, 173 shares of Enovis common stock were withheld in connection with the net settlement of restricted stock units to satisfy tax withholding obligations at a per‑share amount of $26.46. The filing explicitly notes this action does not represent a sale by the reporting person.

After the withholding, Mr. Kleckner beneficially owned 9,834 shares of Enovis common stock, held directly. The Form 4 was signed by attorney‑in‑fact Brian P. Hanigan on 08/07/2025. The filing includes the reporting person’s address in Wilmington, DE.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
insider
Rhea-AI Summary

Ross Terry D, Group President, P&R, of Enovis Corporation (ENOV) reported a Form 4 transaction dated 08/05/2025. The filing shows 325 common shares were withheld by the company to satisfy tax withholding in connection with the net settlement of restricted stock units, at a per-share price of $26.46. Following this withholding, the reporting person is shown as beneficially owning 35,789 shares. The form was filed by one reporting person and signed by attorney-in-fact Brian P. Hanigan on 08/07/2025.

The filing explicitly states the withheld shares do not represent a sale by the reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
insider
-
Rhea-AI Summary

Enovis (ENOV) Q2 2025 10-Q highlights: Net sales grew 7.5% YoY to $564.5 million, led by Reconstructive (+10.7%) and steady Prevention & Recovery (+4.6%). Gross profit rose 15.9% to $334.7 million, lifting gross margin to 59.3% (vs. 55.0%). Operating loss narrowed to $16.8 million from $44.2 million on flat SG&A, but a $10.0 million royalty-buyout charge, higher R&D and intangible amortization kept GAAP earnings negative.

The company reported a net loss attributable to Enovis of $36.7 million (-$0.64 per share) versus $18.6 million (-$0.34) last year, driven by a $10.8 million tax expense versus an $8.9 million benefit in the prior period and hedging losses. Adjusted EBITDA improved 7.7% to $97.1 million. Operating cash flow swung to an inflow of $46.2 million (-$28.4 million LY) as working-capital efficiencies offset higher inventory. Cash ended at $44.1 million; total debt increased to $1.39 billion, lifting net debt by $84 million since year-end.

Balance-sheet expansion reflects completion of seven small acquisitions ($35 million consideration) and Lima integration costs. Inventories climbed 15% YTD, while goodwill and intangibles rose after bolt-on deals. Management remains in compliance with leverage covenants (senior secured leverage ≤3.5×) and has $325 million undrawn on its $900 million revolver.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
quarterly report
-
Rhea-AI Summary

Enovis Corporation (ENOV) filed a Form 8-K on 7 Aug 2025 to furnish Item 2.02 information. The filing states that a press release detailing Q2 FY25 results (quarter ended 4 Jul 2025) was issued the same day and is included as Exhibit 99.1. Management will host a conference call at 8:30 a.m. ET on 7 Aug 2025 to discuss those results. No financial figures, guidance, or qualitative commentary are provided within the 8-K itself. Exhibit 104 indicates the cover page is formatted in Inline XBRL.

The 8-K therefore serves solely as a procedural furnishing of the earnings release and does not, on its own, reveal performance metrics or forward-looking statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
other

FAQ

What is the current stock price of Enovis (ENOV)?

The current stock price of Enovis (ENOV) is $26.95 as of January 12, 2026.

What is the market cap of Enovis (ENOV)?

The market cap of Enovis (ENOV) is approximately 1.7B.
Enovis Corp

NYSE:ENOV

ENOV Rankings

ENOV Stock Data

1.70B
56.28M
1.57%
121.34%
12.07%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WILMINGTON